UY26140A1 - ANTI-TUMOR COMPOUND ACTIVATED BY PAF. - Google Patents

ANTI-TUMOR COMPOUND ACTIVATED BY PAF.

Info

Publication number
UY26140A1
UY26140A1 UY26140A UY26140A UY26140A1 UY 26140 A1 UY26140 A1 UY 26140A1 UY 26140 A UY26140 A UY 26140A UY 26140 A UY26140 A UY 26140A UY 26140 A1 UY26140 A1 UY 26140A1
Authority
UY
Uruguay
Prior art keywords
paf
drug
tumor compound
compound activated
recognized
Prior art date
Application number
UY26140A
Other languages
Spanish (es)
Inventor
Park Reting Lenter Pet Leipert
Original Assignee
Boehringer Ingelheim Pharma
Amp
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Amp, Co Kg filed Critical Boehringer Ingelheim Pharma
Priority to UY26140A priority Critical patent/UY26140A1/en
Publication of UY26140A1 publication Critical patent/UY26140A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un profármaco que es capaz de ser convertido en un fármaco por la acción catalitica de proteínas de activación de fibroblastos humana, reconocido por paf, y siendo dicho fármaco un sitio de escisión que es reconocido por paf.., y siendo dicho fármaco citotóxico o cistotático en condiciones fisiológicasThe invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation proteins, recognized by paf, and said drug being a cleavage site that is recognized by paf .., and being said cytotoxic or cystatic drug under physiological conditions

UY26140A 2000-05-11 2000-05-11 ANTI-TUMOR COMPOUND ACTIVATED BY PAF. UY26140A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY26140A UY26140A1 (en) 2000-05-11 2000-05-11 ANTI-TUMOR COMPOUND ACTIVATED BY PAF.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UY26140A UY26140A1 (en) 2000-05-11 2000-05-11 ANTI-TUMOR COMPOUND ACTIVATED BY PAF.

Publications (1)

Publication Number Publication Date
UY26140A1 true UY26140A1 (en) 2000-12-29

Family

ID=38812188

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26140A UY26140A1 (en) 2000-05-11 2000-05-11 ANTI-TUMOR COMPOUND ACTIVATED BY PAF.

Country Status (1)

Country Link
UY (1) UY26140A1 (en)

Similar Documents

Publication Publication Date Title
AR033792A1 (en) ANTI - TUMORAL COMPOUNDS ACTIVATED BY PAF
CY1114420T1 (en) PHARMACEUTICAL COMPOSITION FOR LEATHER USE INCLUDING KALIPIPOTRIOL AND BETHAMETHASONE FOR HEALTH EDUCATION
BRPI0313733A8 (en) USE OF PROTEIN N BETA KINASE
LV12585A (en) Sustained-release preparation for all antagonist production and use thereof
SV2003001107A (en) IMIDAZOTRIAZINAS REF.LEA 35368
HN1999000124A (en) SUBSTITUTED PYRAZOLE DERIVATIVES.
HN2001000216A (en) PROCESS FOR THE MANUFACTURE OF N-ARIL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES
HN2002000208A (en) 1-RENT OR 1 - CICLOALQUIL-TRIAZOLO [4.3 - a] QUINAZOLIN -5-ONAS AS PHOSPHODIESTERASE INHIBITORS
BR0213684A (en) Use of Endothelin Receptor Antagonists for the Treatment of Tumor Diseases
ES2191449T3 (en) DERIVATIVES OF CICLOPENTABENZOFURANO AND ITS USE.
CY1105142T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
UY27014A1 (en) ANTITUMORAL COMPOUNDS ACTIVATED BY FAP II
UY26140A1 (en) ANTI-TUMOR COMPOUND ACTIVATED BY PAF.
BR0107922A (en) Derivatives of dibenzo [b, f] azepine and their preparation
PA8531601A1 (en) NEW HETEROAROMATOS
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
HN2001000204A (en) AMIDAS OF SUBSTITUTED PHENILCICLOHEXANOCARBOXILICO ACID AND ITS USE
CY1111290T1 (en) 9-ALKYLAMINO-1-NITROACRACIN PRODUCTION
BR0104005A (en) Pharmaceutical composition for the prevention or treatment of a disease associated with an overproduction of il-2
SV2002000639A (en) PHENOXYPHENYL ALCANOSULFONATES REF. READ 34813-SV
ATE339206T1 (en) USE OF LORNOXICAM OR LORNOXICAM ANALOG COMPOUNDS
ATE275551T1 (en) HALOGENPYRIMIDINES
EP3040081A3 (en) Use of protein kinase n beta
GT200000008A (en) PIRAZOLALQUILAMIDAS
DK1838392T3 (en) Selenium-containing drugs for endothelial vascular disease

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101022